.png){kind=icon}
.png){kind=icon}
Return
H3RESCA chelator-enabled [18F]AlF labeling: An optimized temperature-resilient platform for PSMA-targeted PET tracers in prostate cancer
.png){kind=icon}
PRE
AI
Y
张
B
J
J
C
DOI：10.1016/j.nucmedbio.2026.109603.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Objective: Prostate-specific membrane antigen (PSMA) has emerged as a pivotal biomarker for the molecular imaging and targeted therapy of prostate cancer. To address the ongoing need for PSMA-targeting radiotracers with improved mild-labeling capability and reduced non-target organ exposure, beyond currently approved agents (e.g., [68Ga]Ga-PSMA-11) that require higher temperatures or show hepatobiliary clearance, a novel 18F-labeled PSMA inhibitor, [18F]AlF-H3RESCA-PSMA, was developed for PET imaging of prostate cancer.
Journal
IF:
3
Papers:
3.7K
Citations:
3.2K
Organization
Cited Papers